Understanding how large chromosomal deletions affect cancer development in mice
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11041116
This study is looking at how losing big pieces of DNA in our genes can lead to cancer, using special mice to help understand how these changes affect tumor growth, with the hope of finding new ways to treat cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11041116 on ClinicalTrials.gov |
What this research studies
This research investigates the role of large chromosomal deletions in cancer initiation and progression using genetically engineered mouse models. By analyzing the biological and phenotypic impacts of these deletions, the study aims to uncover how they influence tumor suppressor genes and contribute to cancer development. The approach focuses on the integrated effects of multiple gene losses rather than just single gene deletions, potentially revealing new therapeutic opportunities for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that may be influenced by chromosomal deletions, particularly those with aggressive or treatment-resistant forms of the disease.
Not a fit: Patients with cancers that do not involve chromosomal deletions or those whose conditions are not related to the genetic mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer therapy by identifying novel targets for treatment based on the effects of large chromosomal deletions.
How similar studies have performed: Previous research has shown success in understanding the impacts of focal deletions in cancer, but the exploration of large chromosomal deletions is less established and represents a novel approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, MING — DUKE UNIVERSITY
- Study coordinator: CHEN, MING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer Biology, cancer cell genome, cancer genome, cancer initiation